prof dr guy joos dept respiratory medicine ghent university hospital

24
Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital COPD GOLD guidelines

Upload: ivory

Post on 04-Feb-2016

38 views

Category:

Documents


0 download

DESCRIPTION

Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital. COPD GOLD guidelines. Noncommunicable Diseases (NCDs). Responsible for up to 60% of all deaths, 80% are in low- and middle-income countries Major noncommunicable diseases: Cardiovascular disease Cancer - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Prof Dr Guy JOOSDept Respiratory MedicineGhent University Hospital

COPDGOLD guidelines

Page 2: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Noncommunicable Diseases (NCDs)• Responsible for up to 60% of all deaths, 80% are in low- and middle-income

countries

• Major noncommunicable diseases: – Cardiovascular disease– Cancer– Chronic Respiratory disease– Diabetes

• Shared preventable risk factors: – Tobacco use– Unhealthy diet– Physical inactivity – Harmful use of alcohol

Chronic

RespiratoryDiseases

CardiovascularDisease

Diabetes Cancer

Physical inactivity

Obesity

Unhealthy diets

Smoking Harmful use of alcohol

Other NCDs

Page 3: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Global Alliance against Chronic Respiratory Diseaseswww.who.int/respiratory/gard

Disease PrevalenceAsthma 300 millionCOPD 210 millionAllergic rhinitis 400 million

Sleep apnea >100 millionOthers >50 million

Everyone in the world is exposed toCRD risk factors often common with other NCDs

Co-morbidities- paramount importance- often common with other NCDs

GARD (September 2007)GARD (September 2007)

Page 4: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Definition of COPD COPD is a preventable and treatable disease

with some significant extrapulmonary effects that may contribute to the severity in individual patients.

Its pulmonary component is characterized by airflow limitation that is not fully reversible.

The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.GOLD 2006

Page 5: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Lung Pathology in COPDSmall airways and lung parenchyma

Chronic bronchitis Emphysema

Page 6: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Risk Factors for COPD

NutritionNutrition

InfectionsInfections

Socio-economic Socio-economic statusstatus

Aging PopulationsAging Populations

Page 7: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital
Page 8: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Fabbri et al., Eur Respir J, 2008, 31, 204-212

Page 9: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

COPD and Co-Morbidities

COPD patients are at increased risk for: • Myocardial infarction, angina• Osteoporosis• Respiratory infection• Depression• Diabetes• Lung cancer

Page 10: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

COPD and Co-Morbidities

COPD has significant extrapulmonary(systemic) effects including:

• Weight loss• Nutritional abnormalities• Skeletal muscle dysfunction

Page 11: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital
Page 12: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital
Page 13: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

COPD - Deaths / 10001990 Data projected to 2000

Legend<0.62756.275 - 9.6589.659 - 15.68715.688 - 18.14518.146 - 19.88919.89 - 22.11622.117 - 35.54835.549 - 38.177>38.178No Data

Page 14: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

6th leading cause of death worldwide 2.2 million deaths

Mortality related to COPD

Global Burden of Disease Study 1999

Page 15: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

COPD is projected to be the third biggest killer by 2020

Murray & Lopez 1997

Ischemic heart diseaseCVD diseaseLower respiratory infectionDiarrhoeal diseasePerinatal disordersCOPDTuberculosisMeaslesRoad traffic accidentLung cancer

Stomach cancerHIVSuicide

1990 2020

3rd

6th

Page 16: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Causes of death in patients with COPD

Rabe, N Engl J Med, 2007, 356, 851-854

Page 17: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical

Endpoint Committee

McGarvey et al., Thorax, 2007, 62, 411-415

Page 18: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Chronic obstructive pulmonary disease

Page 19: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Chronic overlooked pulmonary disease

Page 20: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

SYMPTOMScough

sputumshortness of breath

EXPOSURE TO RISKFACTORS

tobaccooccupation

indoor/outdoor pollution

SPIROMETRY

Diagnosis of COPD

Page 21: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

• Relieve symptoms • Prevent disease progression• Improve exercise tolerance• Improve health status• Prevent and treat complications• Prevent and treat exacerbations• Reduce mortality

GOALS of COPD MANAGEMENTVARYING EMPHASIS WITH DIFFERING SEVERITY

Page 22: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Four Components of COPD

Management1. Assess and monitor

disease

2. Reduce risk factors

3. Manage stable COPD Education Pharmacologic Non-pharmacologic

4. Manage exacerbations

Page 23: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

Global Initiative for ChronicObstructiveLung Disease

www.goldcopd.com

Page 24: Prof Dr Guy JOOS Dept Respiratory Medicine Ghent University Hospital

IV: Very Severe III: Severe II: Moderate I: MildTherapy at Each Stage of COPD

FEV1/FVC < 70%

FEV1 > 80% predicted

FEV1/FVC < 70%

50% < FEV1 < 80%

predicted

FEV1/FVC < 70%

30% < FEV1 < 50% predicted

FEV1/FVC < 70%

FEV1 < 30% predicted

or FEV1 < 50% predicted plus chronic respiratory failure

Add regular treatment with one or more long-acting bronchodilators (when needed); Add rehabilitation

Add inhaled glucocorticosteroids if repeated exacerbations

Active reduction of risk factor(s); influenza vaccinationAdd short-acting bronchodilator (when needed)

Add long term oxygen if chronic respiratory failure. Consider surgical treatments